Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Stowers Institute for Medical Research, Kansas City, MO, USA.
J Hepatol. 2022 Sep;77(3):619-631. doi: 10.1016/j.jhep.2022.04.010. Epub 2022 Apr 19.
BACKGROUND & AIMS: Vacuole membrane protein 1 (VMP1) is an endoplasmic reticulum (ER) transmembrane protein that regulates the formation of autophagosomes and lipid droplets. Recent evidence suggests that VMP1 plays a critical role in lipoprotein secretion in zebra fish and cultured cells. However, the pathophysiological roles and mechanisms by which VMP1 regulates lipoprotein secretion and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are unknown.
Liver-specific and hepatocyte-specific Vmp1 knockout mice as well as Vmp1 knock-in mice were generated by crossing Vmp1 or Vmp1 mice with albumin-Cre mice or by injecting AAV8-TBG-cre, respectively. Lipid and energy metabolism in these mice were characterized by metabolomic and transcriptome analyses. Mice with hepatic overexpression of VMP1 who were fed a NASH diet were also characterized.
Hepatocyte-specific deletion of Vmp1 severely impaired VLDL secretion resulting in massive hepatic steatosis, hepatocyte death, inflammation and fibrosis, which are hallmarks of NASH. Mechanistically, loss of Vmp1 led to decreased hepatic levels of phosphatidylcholine and phosphatidylethanolamine as well as to changes in phospholipid composition. Deletion of Vmp1 in mouse liver also led to the accumulation of neutral lipids in the ER bilayer and impaired mitochondrial beta-oxidation. Overexpression of VMP1 ameliorated steatosis in diet-induced NASH by improving VLDL secretion. Importantly, we also showed that decreased liver VMP1 is associated with NAFLD/NASH in humans.
Our results provide novel insights on the role of VMP1 in regulating hepatic phospholipid synthesis and lipoprotein secretion in the pathogenesis of NAFLD/NASH.
Non-alcoholic fatty liver disease and its more severe form, non-alcoholic steatohepatitis, are associated with a build-up of fat in the liver (steatosis). However, the exact mechanisms that underly steatosis in patients are not completely understood. Herein, the authors identified that the lack of a protein called VMP1 impairs the secretion and metabolism of fats in the liver and could therefore contribute to the development and progression of non-alcoholic fatty liver disease.
液泡膜蛋白 1(VMP1)是一种内质网(ER)跨膜蛋白,可调节自噬体和脂滴的形成。最近的证据表明,VMP1 在斑马鱼和培养细胞中的脂蛋白分泌中起着关键作用。然而,VMP1 调节非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)中脂蛋白分泌和脂质积累的病理生理作用和机制尚不清楚。
通过将 Vmp1 或 Vmp1 小鼠与白蛋白-Cre 小鼠交配或分别注射 AAV8-TBG-cre,生成肝特异性和肝细胞特异性 Vmp1 敲除小鼠和 Vmp1 敲入小鼠。通过代谢组学和转录组学分析来描述这些小鼠的脂质和能量代谢。还对喂养 NASH 饮食的肝过表达 VMP1 的小鼠进行了特征描述。
肝细胞特异性缺失 Vmp1 严重损害了 VLDL 分泌,导致大量肝脂肪变性、肝细胞死亡、炎症和纤维化,这些都是 NASH 的特征。从机制上讲,Vmp1 的缺失导致肝内磷脂酰胆碱和磷脂酰乙醇胺水平降低,以及磷脂组成发生变化。Vmp1 在小鼠肝脏中的缺失也导致 ER 双层中中性脂质的积累和线粒体β-氧化受损。VMP1 的过表达通过改善 VLDL 分泌改善了饮食诱导的 NASH 中的脂肪变性。重要的是,我们还表明,肝脏中 VMP1 的减少与人类的 NAFLD/NASH 有关。
我们的结果提供了关于 VMP1 在调节 NAFLD/NASH 发病机制中肝磷脂合成和脂蛋白分泌的新见解。
非酒精性脂肪性肝病及其更严重的形式,非酒精性脂肪性肝炎,与肝脏脂肪堆积(脂肪变性)有关。然而,导致患者脂肪变性的确切机制尚不完全清楚。在此,作者发现一种叫做 VMP1 的蛋白质缺失会损害肝脏中脂肪的分泌和代谢,因此可能导致非酒精性脂肪性肝病的发生和发展。